Psychedelics and ketamine as plasticity openers, not magic cures

Ketamine, psilocybin and MDMA start a process of brain change. They are not the change itself. Each acts on a different receptor, yet across six Huberman Lab conversations all three are described as openers of plasticity whose benefit depends on what happens afterward: therapy, integration and how a person lives.

Andrew Huberman's account of ketamine is the most detailed. It blocks NMDA receptors, which are needed for plasticity, and still relieves depression. It binds those receptors on inhibitory neurons, which lets mood circuits fire in bursts and release the growth factor BDNF. Relief can begin within minutes, but a single dose usually wears off in three days to a week. Repeated clinical sessions give relief that can last weeks or months, which he attributes to circuit rewiring that takes many days. In one study, blocking opioid receptors left the euphoria and dissociation intact but removed the antidepressant effect, so the vivid experience may not be what heals. The circuits involved respond to thinking and behavior, and the drug only biases them. His closing line is "better living through chemistry still requires better living".

On psilocybin, Huberman describes selective activation of serotonin 2A receptors, more communication across brain regions and growth of dendritic spines in mice. He calls psychedelics a wedge under the boulder of neuroplasticity. Where the boulder rolls depends on the person, and rewiring is not automatically good. In trials, about two sessions with supportive therapy bring substantial relief to roughly 60 to 75 percent of people with major depression.

On MDMA, he says it floods the brain with serotonin and dopamine, lowers threat responses and makes people more willing to trust. But MDMA taken on its own does not cure PTSD. It augments talk therapy, and the trial protocol wraps each dosing in preparation and integration sessions.

Robin Carhart-Harris of UCSF shows that psilocybin's opening of brain networks persists for weeks and tracks improvement. He puts more weight on the experience itself, since its strength and the patient's trust predict outcomes. He is blunt about afterward, quoting "after the ecstasy, the laundry". In treatment-resistant depression, relapse by three months is more the rule than the exception. Neuralink neurosurgeon Matthew MacDougall adds that drugs, not electrodes, are the most promising way to boost adult plasticity, because a drug reaches the whole brain.

They agree that the drugs start rewiring, that effects fade without follow-through, and that microdosing is unproven. They differ in emphasis on how much the trip matters.

This applies to clinical conditions treated with human support, not to recreational or at-home use. Street drugs can contain fentanyl. People with a personal or family history of psychosis or bipolar disorder, the young, pregnant women and those with seizure or heart risks are typically excluded. Anyone considering these treatments should work only with qualified clinicians and talk to a doctor or psychiatrist before changing any medication.

What to do with it: treat the session as the start of the work. Plan the days and weeks after it. Add sleep, morning light, good food and social contact. Build trust with the therapists first. Take notes and act on them. Turn integration into a lasting practice, and expect that relapse is possible.